Literature DB >> 11426540

Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.

E Montefusco1, F Fazi, I Cordone, C Ariola, M Nanni, A Spadea, M A Spiriti, S Fenu, F Mandelli, M C Petti.   

Abstract

The occurrence of acute myeloid leukemia (AML) as a secondary tumor has been frequently reported in patients who received various chemotherapy regimens for hematologic malignancies wile the concomitant development of chronic lymphoproliferative diseases (CLD) and AML in previously untreated patients is extremely rare. We report a case with an apparently spontaneous occurrence of AML and non Hodgkin low-grade lymphoma diagnosed by immunological, cytogenetical and molecular analyses. In particular genetic studies allowed to identify the coexistence of a clonal lymphoid population and a myeloid blast component characterized by inv(16) marker and CBFbeta-MYH11 gene fusion. Complete remission of AML and the CLD was obtained following high doses of hydroxyurea and two consolidation cycles of fludarabine plus intermediate dose cytarabine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11426540     DOI: 10.3109/10428190109097666

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report.

Authors:  Gyeongmin Jeong; Jinhyong Kim; Seeun Han; Jongmin Lee; Kyunghye Park; Chuiyong Pak; Ji-Hun Lim; Hee Jeong Cha; Hawk Kim; Jae-Cheol Jo
Journal:  Oncol Lett       Date:  2015-12-21       Impact factor: 2.967

Review 2.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

Review 3.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

4.  Philadelphia chromosome with acute myeloid leukemia and concurrent large B cell lymphoma of different origins: A case report.

Authors:  Yang Dai; Xiao Shuai; Pu Kuang; Lin Wang; Ting Liu; Ting Niu
Journal:  Oncol Lett       Date:  2017-01-10       Impact factor: 2.967

5.  Analyses and treatment of simultaneous bi-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review.

Authors:  Xiaorui Fu; Yufeng Shang; Lei Zhang; Ling Li; Xin Li; Xinhua Wang; Zhenchang Sun; Mingzhi Zhang
Journal:  Oncol Lett       Date:  2018-09-18       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.